
    
      The purpose of this study is to determine the value of adding IMC-A12 to irinotecan +
      cetuximab in improving progression-free survival (PFS) at 18 weeks from the date of
      randomization for participants with metastatic Kirsten Rat Sarcoma (K-RAS) wild-type CRC that
      has progressed on an oxaliplatin/bevacizumab-containing regimen.
    
  